---
title: A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
nct_id: NCT07324616
overall_status: RECRUITING
phase: PHASE1
sponsor: Edgewise Therapeutics, Inc.
study_type: INTERVENTIONAL
primary_condition: Hepatic Impairment (HI)
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07324616.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07324616"
ct_last_update_post_date: 2026-03-09
last_seen_at: "2026-05-12T07:27:29.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

**Official Title:** A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of EDG-7500 in Participants With Impaired and Normal Hepatic Function

**NCT ID:** [NCT07324616](https://clinicaltrials.gov/study/NCT07324616)

## Key Facts

- **Status:** RECRUITING
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 32
- **Lead Sponsor:** Edgewise Therapeutics, Inc.
- **Conditions:** Hepatic Impairment (HI)
- **Start Date:** 2026-01-26
- **Completion Date:** 2026-05
- **CT.gov Last Update:** 2026-03-09

## Brief Summary

The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of liver function impairment versus participants with normal liver function. The safety of EDG-7500 in adult participants with different levels of liver function impairment will also be evaluated in this study.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

All Participants

* Adult, male or female, ≥ 18 years of age.
* Female and male participants must follow protocol-specified contraception guidance.
* Continuous non-smoker or moderate smoker (≤ 10 cigarettes per day or equivalent) for at least 3 months prior to dosing.
* BMI ≥ 18.0 and ≤ 40.0 kg/m2 at screening.
* eGFR \>60 mL/min calculated using the 2021 CKD-EPI creatinine equation.

Participants with Mild and Moderate Hepatic Impairment (HI)

* With the exception of HI, is in generally good health for study participation including the following:

  * Pulse rate is ≥ 40 bpm and ≤ 110 bpm at screening.
  * QTcF interval is ≤ 500 msec and has ECG findings considered normal or not clinically significant.
* Has impaired hepatic function as defined by the Child-Pugh classification for severity of liver disease and has a Child-Pugh score in line with one of the following HI cohorts at screening:

  * Mild HI (Class A): Child-Pugh score of 5 to 6, inclusive.
  * Moderate HI (Class B): Child-Pugh score of 7 to 9, inclusive.
* Has a diagnosis of chronic (\> 6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) hepatic insufficiency.

Participants with Normal Hepatic Function:

-Medically healthy, including the following:

* Blood pressure is ≥ 90/40 mmHg and ≤ 150/95 mmHg.
* Pulse rate is ≥ 40 bpm and ≤ 100 bpm.
* QTcF interval is ≤ 470 msec and has ECG findings considered normal or not clinically significant.
* Liver function test including ALT ≤ ULN, AST ≤ ULN, and total bilirubin ≤1.5x ULN.

Exclusion Criteria:

All Participants

* History or presence of alcohol or drug abuse within the past 1 year prior to dosing.
* Female participant with a positive pregnancy test at the screening visit or at check-in or who is lactating or breastfeeding.
* Positive urine or breath alcohol results at screening or check-in. Unable to refrain from or anticipates the use of any drugs.
* Positive results for HIV at screening.
* Donation of blood or significant blood loss within 56 days prior to dosing.
* Plasma donation within 7 days prior to dosing.
* Participation in another clinical study within 30 days or within 5 half-lives (if known), prior to dosing.

Participants with Mild and Moderate HI

* With the exception of HI, history or presence of clinically significant medical or psychiatric condition or disease, or any illness that might confound the results of the study or poses an additional risk to the participant by their participation in the study.
* History of severe complications of liver disease within the preceding 3 months of screening.
* Primary biliary cholangitis or biliary obstruction at screening.
* Fluctuating or rapidly deteriorating hepatic function from screening until prior to dosing.
* History of liver or other solid organ transplantation.
* Requires paracentesis more often than 2 times per month.
* Transjugular intrahepatic portosystemic shunt and/or has undergone portacaval shunting within 90 days prior to screening.
* Received antiviral and/or immune modulating therapy for active hepatitis infection within 90 days prior to dosing.
* Diabetic participants with HbA1c \> 8.5% at screening.
* Positive for HBsAg or HBcAb and has positive hepatitis B virus DNA at screening.
* Positive for HCV and has a detectable HCV viral load at screening.

Participants with Normal Hepatic Function

* History or presence of clinically significant medical or psychiatric condition or disease, or any illness that might confound the results of the study or poses an additional risk to the participant by their participation in the study.
* Alcohol consumption \> 14 drinks per week for males (7 for females) within 45 days of screening.
* Positive result for HBsAg or HCV at screening.
```

## Arms

- **Healthy Adults** (EXPERIMENTAL)
- **Mild Hepatic Impairment** (EXPERIMENTAL)
- **Moderate Hepatic Impairment** (EXPERIMENTAL)

## Interventions

- **EDG-7500** (DRUG) — Single dose of EDG-7500

## Primary Outcomes

- **Area under the plasma concentration time-curve from time zero to the last measured concentration (AUC0-last)** _(time frame: Pre-dose to day 10)_
- **Area under the plasma concentration time-curve from time zero extrapolated to infinity (AUC0-inf)** _(time frame: Pre-dose to day 10)_
- **Maximum observed plasma concentration (Cmax)** _(time frame: Pre-dose to day 10)_

## Secondary Outcomes

- **Safety: incidence of treatment-emergent adverse events** _(time frame: Up to 14 days of monitoring)_

## Locations (2)

- The University of Miami Division of Clinical Pharmacology, Miami, Florida, United States — _RECRUITING_
- Orlando Clinical Research Center, Orlando, Florida, United States — _RECRUITING_

## Recent Field Changes (last 30 days)

- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.the university of miami division of clinical pharmacology|miami|florida|united states` — added _(2026-05-12)_
- `locations.orlando clinical research center|orlando|florida|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07324616.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07324616*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*